文献速递类风湿关节炎

TOZURA研究中合并糖皮质激素对皮下托珠单抗治疗类风湿关节炎的影响

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

TOZURA项目的事后分析评估了皮下托珠单抗(TCZ-SC)单药或联合传统合成改善病情抗风湿药(csDMARDs)治疗类风湿关节炎(RA)时,按基线糖皮质激素(GC)使用分层的疗效与安全性。共1804例患者接受TCZ-SC 162 mg每周一次,结果显示无论是否使用GC,从基线至第24周达到DAS28-ESR<2.6临床缓解的比例相似增加,患者报告结局改善相似,总体不良事件谱基本相似。

要点

  • TCZ-SC单药或联合csDMARDs治疗RA时,合并口服GC(≤10 mg/天泼尼松等效)与未合并GC者的疗效增量相似。
  • 各亚组从基线至第24周达到DAS28-ESR<2.6临床缓解的比例均相似增加。
  • GC与非GC亚组总体不良事件谱基本相似,仅存在轻微数值差异。

核心结论

  • TCZ-SC单药及联合csDMARDs的疗效增量在既往及继续口服GC与未使用GC的患者间相似,安全性谱总体相似。

研究设计与样本

  • TOZURA为多国、开放标签、单臂、共同框架研究项目(11项方案,22个国家),纳入中度至重度RA且csDMARDs或生物制剂治疗失败或MTX初治的患者。
  • 患者接受每周一次TCZ-SC 162 mg治疗≥24周,作为单药或联合csDMARDs和/或口服GC(≤10 mg/天泼尼松等效),GC需继续不变使用24周。
  • 按基线GC使用定义治疗亚组,共1804例接受TCZ-SC的患者纳入疗效与安全性分析。

主要发现

  • 1804例患者中,单药+GC组145例,单药无GC组208例,联合治疗+GC组730例,联合治疗无GC组721例。
  • 两个GC亚组的中位GC剂量均为5 mg/天。
  • 从基线至第24周,所有亚组达到DAS28-ESR<2.6临床缓解的比例相似增加,患者报告结局改善相似。
  • GC与非GC亚组总体不良事件谱基本相似,仅存在轻微数值差异。

关键数值与推荐

  • 临床缓解定义为DAS28-ESR<2.6。
  • 口服GC剂量限制为≤10 mg/天泼尼松等效,且需继续不变使用24周。
  • TCZ-SC剂量为每周一次162 mg,治疗≥24周。

临床怎么用

  • 对于中度至重度RA患者,无论是否合并口服GC(≤10 mg/天泼尼松等效),TCZ-SC单药或联合csDMARDs均可考虑使用。
  • 合并GC者使用TCZ-SC时无需因GC使用而调整治疗预期,疗效与安全性总体相似。

局限性

  • 本研究为事后分析,非随机分组,GC使用由基线临床决定。
  • 研究为开放标签、单臂设计,未设对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This post hoc analysis of the TOZURA study programme evaluated the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or with concomitant conventional synthetic DMARDs (csDMARDs) in patients with RA categorized by baseline glucocorticoid (GC) use. METHODS: TOZURA was a multinational, open-label, single-arm, common-framework study programme (11 protocols, 22 countries) in patients with moderate to severe RA in whom csDMARDs or biologic therapies had failed or who were MTX naïve. Patients received once-weekly TCZ-SC 162 mg for ⩾24 weeks as monotherapy or in combination with csDMARDs and/or oral GC use (⩽10 mg/day prednisone or equivalent), which was to be continued unchanged for 24 weeks. Treatment subgroups were defined by baseline GC use and analysed for efficacy and safety. RESULTS: Of 1804 patients who received TCZ-SC, 145 received monotherapy + GC, 208 received monotherapy without GC, 730 received combination therapy + GC and 721 received combination therapy without GC. The median GC dose in both GC subgroups was 5 mg/day. The proportion of patients who achieved clinical remission, defined as DAS in 28 joints using ESR <2.6, increased similarly from baseline to week 24 in all subgroups. Improvements in patient-reported outcomes were similar in all subgroups. Overall adverse event profiles were generally similar between subgroups, with some slight numerical differences between GC and non-GC subgroups. CONCLUSION: The incremental efficacy benefits of TCZ-SC as monotherapy and in combination with csDMARDs were similar between patients with and without previous and continued oral GC treatment, with generally similar safety profiles. TRIAL REGISTRATION: ClinicalTrials.gov, http://www.clinicaltrials.gov, NCT01941940, NCT01941095, NCT01951170, NCT01987479, NCT01988012, NCT01995201, NCT02001987, NCT02011334, NCT02031471, NCT02046603, NCT02046616.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Choy E, Caporali R, Xavier R, et al. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019. PMID: 30649524. doi:10.1093/rheumatology/key393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。